These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27616890)

  • 1. The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a meta-analysis.
    Song XY; Li BY; Zhou EX; Wu FX
    Onco Targets Ther; 2016; 9():5339-47. PubMed ID: 27616890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.
    Lu DG; Ma YM; Zhu AJ; Han YW
    Oncotarget; 2017 Mar; 8(13):22166-22174. PubMed ID: 27825140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance and potential drug target of RUNX3 in breast cancer.
    Yu YY; Chen C; Kong FF; Zhang W
    Drug Des Devel Ther; 2014; 8():2423-30. PubMed ID: 25525332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of PTEN hypermethylation and breast cancer: a meta-analysis.
    Luo S; Chen J; Mo X
    Onco Targets Ther; 2016; 9():5643-50. PubMed ID: 27672335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
    Su Y; Wang X; Li J; Xu J; Xu L
    Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
    Xu L; Lan H; Su Y; Li J; Wan J
    Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
    Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
    Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
    Huang R; Ding P; Yang F
    Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis.
    Mu WP; Wang J; Niu Q; Shi N; Lian HF
    Onco Targets Ther; 2014; 7():1237-45. PubMed ID: 25053885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma.
    Yang Y; Ye Z; Zou Z; Xiao G; Luo G; Yang H
    Tumour Biol; 2014 Oct; 35(10):10333-40. PubMed ID: 25037468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between the methylation status of Runx3 gene and positive expression of estrogen receptor in breast cancer].
    Yan Z; Gao S; Wu X; Liu H
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):240-4. PubMed ID: 25975905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer.
    Liu H; Yan Z; Yin Q; Cao K; Wei Y; Rodriguez-Canales J; Ma D; Wu Y
    J Histochem Cytochem; 2018 Oct; 66(10):709-721. PubMed ID: 30133331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methylation of Runx3 promoter in different breast lesions].
    Wang X; Zheng X; Lin X; Shi Y; He Y; Chen G
    Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):447-50. PubMed ID: 25327792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma.
    Long C; Yin B; Lu Q; Zhou X; Hu J; Yang Y; Yu F; Yuan Y
    Cancer Invest; 2007 Dec; 25(8):685-90. PubMed ID: 18058463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Runt-related Transcription Factor 3 Promoter Hypermethylation and Gastric Cancer Risk: A Meta-analysis.
    Lina M; Changan W; Qing Z
    Open Life Sci; 2018 Jan; 13():64-70. PubMed ID: 33817069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Protein Expression and Methylation of DAPK1 with Clinicopathological Features in Invasive Ductal Carcinoma Patients from Kashmir.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Zargar MA
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):839-848. PubMed ID: 30912402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.
    Goel A; Arnold CN; Tassone P; Chang DK; Niedzwiecki D; Dowell JM; Wasserman L; Compton C; Mayer RJ; Bertagnolli MM; Boland CR
    Int J Cancer; 2004 Dec; 112(5):754-9. PubMed ID: 15386381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma.
    Oshimo Y; Oue N; Mitani Y; Nakayama H; Kitadai Y; Yoshida K; Ito Y; Chayama K; Yasui W
    Pathobiology; 2004; 71(3):137-43. PubMed ID: 15051926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.
    Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E
    Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.